NCT03352531已完成1 期
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 99
- 试验地点
- 5
- 主要终点
- Number of participants with adverse events (AEs)
研究概览
简要总结
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK105 as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK105 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK105 as a single agent at the MTD or RP2D.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- •In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- •In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.
- •Subject must have at least one measurable lesion according to RECIST Version1.
- •Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
- •Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy.
- •Adequate organ function.
排除标准
- •History of severe hypersensitivity reactions to other mAbs.
- •For dose-escalation phase (Phase 1a), prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody. For dose-expansion phase (Phase 1b), prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or agonists such as CD40, CD137, GITR, OX40 etc.
- •Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK
- •Prior treatment with systemic immune modulating agents (other than agents specified above) that was within 28 days prior to enrollment, or within 90 days prior to enrollment if there was an immune related adverse event, or associated with toxicity that resulted in discontinuation of the immune modulating agent.
- •Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer related conditions is acceptable.
- •Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
- •Active or prior documented autoimmune disease within the past 2 years.
- •Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
- •History of primary immunodeficiency.
- •History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives.
- •Known allergy or reaction to any component of the AK105 formulation.
- •History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
- •Known history of tuberculosis.
- •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- •Known active hepatitis B or C infections, or any positive test at screening for hepatitis B or C virus indicating acute or chronic infection except for subjects with HCC. Subjects with past or resolved HBV infection are eligible. Subjects positive for HCV antibody are eligible only if qualitative HCV RNA tests is negative.
- •An active infection requiring systemic therapy with the exception of antiviral therapy for hepatitis as specified by the protocol.
- •Receipt of live or attenuated vaccination within 30 days prior to the first dose of AK
- •Active or prior documented esophageal or gastric variceal bleeding
- •Clinically apparent ascites on physical examination. Ascites that requires active ongoing paracentesis (within 6 weeks prior to the first scheduled dose) to control symptoms. Note: ascites detectable on imaging studies only are allowed.
- •Portal vein invasion at the main portal (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging.
- •Clinically diagnosed hepatic encephalopathy characterized by asterixis.
研究组 & 干预措施
AK-105
Experimental
Single-arm
干预措施: AK-105 (Biological)
结局指标
主要结局
Number of participants with adverse events (AEs)
时间窗: From the time of informed consent signed through 90 days after the last dose of AK105
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Number of participants with a Dose Limiting Toxicity (DLT)
时间窗: During the first 4 weeks
DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
次要结局
- Objective response rate (ORR)(Up to 2 years)
- Area under the curve (AUC) of AK105(From first dose of AK105 through 30 days after last dose of AK105)
- Number of subjects who develop detectable anti-drug antibodies (ADAs)(From first dose of AK105 through to 90 days after last dose of AK105)
- Disease control rate (DCR)(Up to 2 years)
- Progression-free survival (PFS)(Up to 2 years)
- Overall survival (OS)(Up to 2 years)
- Maximum observed concentration (Cmax) of AK105(From first dose of AK105 through 30 days after last dose of AK105)
- Minimum observed concentration (Cmin) of AK105 at steady state(From first dose of AK105 through 30 days after last dose of AK105)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsAdvanced CancerNCT03261011Akesobio Australia Pty Ltd119
已完成
1 期
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsNeoplasms MalignantNCT04047290Akesobio Australia Pty Ltd80
已完成
早期 1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursAdvanced or Metastatic Solid TumoursNCT05021120Akesobio Australia Pty Ltd67
Unknown
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114Advanced or Metastatic Solid TumorsMalignancyMetastasisNCT05200273Akeso30
已完成
1 期
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsSolid TumorsNCT04774952Revolution Medicines, Inc.58